摘要
目的：对比前列地尔与科素亚治疗早期糖尿病肾病的疗效。方法：随即选取我院2007年1月到2009年3月间早期糖尿病肾病患者104例，分为前列地尔治疗组和科素亚治疗组；前列地尔治疗组以前列地尔治疗早期糖尿病肾病，科素亚治疗组以科素亚治疗早期糖尿病肾病，治疗之一个疗（15d）程之后分析比较前列地尔与科素亚治疗早期糖尿病肾病的疗效。结果：前列地尔治疗组：治疗前后血压、血糖、24h尿白蛋白及血肌酐下降明显（P〈0．01）、血脂有轻度下降但无统计学差异（P〉0．05）；科素亚治疗组：早期糖尿病肾病患者经科素亚治疗后，UAlb排出量，尿UAlb／Cr，尿TGF-β1，CⅣ和LAM均明显低于治疗前（P〈0．05），证实此类药物能够显著减少患者UAlb排出量，减少尿TGF-β1的分泌，降低C1v和LAM的含量。结论：两者对早期糖尿病肾病的疗效虽然有细微差别，但是效果都比较明显，值得推广。
Objective：alprostadil compared with losartan in the treatment of early diabetic nephropathy. Method： then select the hospital in January 2007 to March 2009 among 104 patients with early diabetic nephropathy patients were divided into alprostadil losartan treatment group and treatment group; alprostadil group alprostadil treatment of early diabetic nephropathy, losartan treatment group Losartan treatment of early diabetic nephropatby, treatment of a treatment （15d） after the process of analysis and comparison of alprostadil treatment with losartan in diabetic nephropathy. Results alprostadil treatment group： before and after treatment of blood pressure, blood sugar, 24h urinary albumin and serum creatinine decreased significantly （ P 〈0.01）, triglyceride decreased slightly but not significantly different （ P〉0.05） ; losartan treatment Group： Early diabetic nephropathy patients after losartan treatment, UAIb excretion, urine UAlb / Cr, urinary TGF-α, CIV and LAM was significantly lower than before treatment （ P 〈0. 05）, confirmed that these drugs can significantly reduce patient UAlb excretion, reduced urinary TGF-α secretion, reduce the content of CIV and LAM. Conelusion; two pairs of early diabetic nephropathy despite minor differences, but are rather obvious, worthy of promotion.
出处
《医学信息（下旬刊）》
2010年第7期60-60,62,共2页
Medical information
